A Phase 3 interventional study of Sham and Therapeutic Plasma Exchange in Aging, sponsored by Dobri Kiprov. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-02.
Sponsored by Dobri Kiprov · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to assure the safety of long term therapeutic plasma exchange (TPE) with and without Intravenous Immunoglobulin (IVIG) and its effects on biomarkers and epigenetic biologic clocks in forty individuals. The main question is to assure the safety from long term TPE using changes in clinical and laboratory outcomes and also evaluating changes on additional blood biomarkers and epigenetic clocks during and after TPE treatment. Researchers will compare the TPE treatment group to the Sham treatment group to identify changes due to TPE. Participants will receive six TPE or Sham treatments over one of two treatment schedules and may receive IVIG with treatment.
This is the only study on the registry with Dobri Kiprov as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
will receive 6 monthly TPE procedures (TOTAL 6 treatments)
Device: Therapeutic Plasma Exchange
will receive 2 TPE procedures in one week. The same treatment will be repeated on a monthly basis two more times (Two treatments per month for three months to total 6 treatments)
Device: Therapeutic Plasma Exchange
will receive 2 TPE procedures followed by 2 gm of IVIG in one week. The same treatment will be repeated on a monthly basis twice more. (Two TPE procedures per month for three months - total of 6 treatments)
Device: Therapeutic Plasma Exchange · Drug: IVIG
Sham TPE PROCEDURE once a month for 6 months (total of 6 treatments)
Device: Sham
The patient's blood will not circulate through the apheresis machine. The patient will receive approximately 250 cc of normal saline during each sham pheresis procedure.
Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.
Intravenous Immunoglobulin
Adverse events and unanticipated events total for TPE safety
The primary objective is to assure the safety of long term TPE
Time frame: through study completion, an average of 1 year
Rate of change to blood epigenetic clock from TPE
The objective is to compare the rate of change to the blood epigenetic clock from TPE.
Time frame: through study completion, an average of 1 year
Change in hand grip strength
The objective is to compare changes in hand grip strength from TPE
Time frame: after study completion, an average of 2 years
Change in time up and go test
The objective is to compare changes in the time up and go test from TPE
Time frame: after study completion, an average of 2 years
Change in balance time
The objective is to compare changes in balance time from TPE
Time frame: after study completion, an average of 2 years
Change in short-form health survey score
The objective is to compare changes in short-form health survey scores from TPE, with higher scores being better
Time frame: after study completion, an average of 2 years
Ran from Sep 2022 to primary completion in Nov 2023, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous